Cargando…

Simulation Modeling to Extend Clinical Trials of Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Early Breast Cancer

PURPOSE: The Trial Assigning Individualized Options for Treatment (TAILORx) found chemotherapy could be omitted in many women with hormone receptor–positive, HER2-negative, node-negative breast cancer and 21-gene recurrence scores (RS) 11–25, but left unanswered questions. We used simulation modelin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jayasekera, Jinani, Sparano, Joseph A, Gray, Robert, Isaacs, Claudine, Kurian, Allison, O’Neill, Suzanne, Schechter, Clyde B, Mandelblatt, Jeanne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049983/ https://www.ncbi.nlm.nih.gov/pubmed/32337487 http://dx.doi.org/10.1093/jncics/pkz062

Ejemplares similares

Development and Validation of a Simulation Model–Based Clinical Decision Tool: Identifying Patients Where 21-Gene Recurrence Score Testing May Change Decisions
por: Jayasekera, Jinani, et al.
Publicado: (2021)

Simulation modeling of breast cancer endocrine therapy duration by patient and tumor characteristics
por: Chandler, Young, et al.
Publicado: (2021)

Reassessing the Benefits and Harms of Risk-Reducing Medication Considering the Persistent Risk of Breast Cancer Mortality in Estrogen Receptor–Positive Breast Cancer
por: Jayasekera, Jinani, et al.
Publicado: (2023)

Reflecting on 20 years of breast cancer modeling in CISNET: Recommendations for future cancer systems modeling efforts
por: Trentham-Dietz, Amy, et al.
Publicado: (2021)

A scoping review of interactive and personalized web-based clinical tools to support treatment decision making in breast cancer
por: Zhao, Amy, et al.
Publicado: (2021)

Effect of Personalized Breast Cancer Risk Tool on Chemoprevention and Breast Imaging: ENGAGED-2 Trial
por: Wernli, Karen J, et al.
Publicado: (2021)

Psychosocial and Quality of Life in Women Receiving the 21-Gene Recurrence Score Assay: The Impact of Decision Style in Women with Intermediate RS
por: Sulayman, Nadiyah, et al.
Publicado: (2012)

Cost-Effectiveness of a Telephone-Based Smoking Cessation Randomized Trial in the Lung Cancer Screening Setting
por: Cao, Pianpian, et al.
Publicado: (2022)

Using Protection Motivation Theory to Predict Intentions for Breast Cancer Risk Management: Intervention Mechanisms from a Randomized Controlled Trial
por: Conley, Claire C., et al.
Publicado: (2021)

Progress in adjuvant chemotherapy for breast cancer: an overview
por: Anampa, Jesus, et al.
Publicado: (2015)

Endocrine therapy initiation, discontinuation and adherence and breast imaging among 21-gene recurrence score assay-eligible women under age 65
por: O’Neill, Suzanne C., et al.
Publicado: (2017)

Which Strategies Reduce Breast Cancer Mortality Most?: Collaborative Modeling of Optimal Screening, Treatment, and Obesity Prevention
por: Mandelblatt, Jeanne, et al.
Publicado: (2013)

Epidemiological Determinants of Advanced Prostate Cancer in Elderly Men in the United States
por: Jayasekera, Jinani, et al.
Publicado: (2019)

Impact of the COVID-19 Pandemic on Breast Cancer Mortality in the US: Estimates From Collaborative Simulation Modeling
por: Alagoz, Oguzhan, et al.
Publicado: (2021)

Collaborative modeling of the impact of obesity on race-specific breast cancer incidence and mortality
por: Chang, Yaojen, et al.
Publicado: (2012)

An ecological approach to monitor geographic disparities in cancer outcomes
por: Jayasekera, Jinani, et al.
Publicado: (2019)

3367 A Mouse Model of APOE Genotype in Chemotherapy Related Cognitive Impairment
por: Demby, Tamar, et al.
Publicado: (2019)

Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer
por: Sparano, Joseph A., et al.
Publicado: (2021)

Evidence-based sizing of non-inferiority trials using decision models
por: Lansdorp-Vogelaar, Iris, et al.
Publicado: (2019)

Psychoneuroimmunology-Based Stress Management during Adjuvant Chemotherapy for Early Breast Cancer
por: Robins, Jo Lynne W., et al.
Publicado: (2013)

Understanding the Needs of Young Women Regarding Breast Cancer Risk Assessment and Genetic Testing: Convergence and Divergence among Patient-Counselor Perceptions and the Promise of Peer Support
por: Evans, Chalanda, et al.
Publicado: (2016)

Adjuvant chemotherapy
por: Glimelius, B.
Publicado: (2013)

Chemotherapy promotes astrocytic response to Aβ deposition, but not Aβ levels, in a mouse model of amyloid and APOE
por: Ng, Christi Anne S., et al.
Publicado: (2022)

Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review
por: Caswell-Jin, Jennifer L, et al.
Publicado: (2018)

Outcomes and quality of life following breast cancer treatment in older women: When, why, how much, and what do women want?
por: Mandelblatt, Jeanne, et al.
Publicado: (2003)

Prognostic gene expression assays in breast cancer: are two better than one?
por: Sparano, Joseph A.
Publicado: (2018)

Personalizing Breast Cancer Screening Based on Polygenic Risk and Family History
por: van den Broek, Jeroen J, et al.
Publicado: (2020)

21-Gene Recurrence Score and Adjuvant Chemotherapy Decision for Breast Cancer Patients with Positive Lymph Nodes
por: Tong, Yiwei, et al.
Publicado: (2019)

Use of 21-gene recurrence score assay to individualize adjuvant chemotherapy recommendations in ER+/HER2− node positive breast cancer—A National Cancer Database study
por: Peethambaram, Prema P., et al.
Publicado: (2017)

21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer
por: Geyer, Charles E., et al.
Publicado: (2018)

Efficacy of adjuvant chemotherapy stratified by age and the 21-gene recurrence score in estrogen receptor-positive breast cancer
por: Yu, Jing, et al.
Publicado: (2021)

Letrozole in the extended adjuvant setting: MA.17
por: Goss, Paul E.
Publicado: (2007)

Letrozole in the extended adjuvant setting: MA.17
por: Goss, Paul E.
Publicado: (2008)

Adjuvant chemotherapy for colorectal cancer
por: Maughan, T S
Publicado: (2001)

Lymphadenectomy and adjuvant therapy in endometrial carcinoma: role of adjuvant chemotherapy
por: Otsuka, I, et al.
Publicado: (2002)

Containerization as a means of extending the lifetime of HDL development tools
por: Laforge, Clyde
Publicado: (2023)

QS-21: A Potent Vaccine Adjuvant
por: Zhu, Daming, et al.
Publicado: (2015)

Trends in utilization of neoadjuvant and adjuvant chemotherapy for muscle invasive bladder cancer
por: McFerrin, Coleman, et al.
Publicado: (2020)

Trade-Offs Between Harms and Benefits of Different Breast Cancer Screening Intervals Among Low-Risk Women
por: van Ravesteyn, Nicolien T, et al.
Publicado: (2021)

The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use
por: Eiermann, W., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_8bi0li8cknn9kevk3789lj2gmc